Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Cellares raises $277 million in its Series D round, with ARK Invest contributing $20 million. The funding will support advancements in cell therapy manufacturing.
Amount Raised
$277 Million
Round Type
Series D
South San FranciscoManufacturingBiotechnologyInvestors
Description
Cellares has secured $277 million in its Series D financing, including a $20 million investment from ARK Invest. The funds will be used to enhance cell therapy manufacturing capabilities and support commercial-scale operations. Cellares is focused on transforming the manufacturing process with automation and innovation. This funding comes as the company signs a 10-year supply agreement with Cabaletta Bio and delivers its first doses to patients.
Fundz sees it the moment Cellares raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Cellares raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.